Marex Group (MRX) Company Report

Faruqi & Faruqi, LLP is investigating Marex Group plc (NASDAQ: MRX) for potential federal securities law violations, with a deadline for lead plaintiff applications set for December 8, 2025.
The investigation follows an August 5, 2025, NINGI Research report alleging a multi-year accounting scheme, including the sale of over-the-counter financial instruments to itself, inconsistencies in financial statements, and concealed derivatives exposure.
Specific allegations from the report include a $17 million fabricated receivable and nearly $1 billion in concealed derivatives exposure.
Following the report, Marex's stock dropped 6.2%, closing at $35.31.

Nov 21, 2025, 3:37 PM

Press Release

Faruqi & Faruqi Investigates Marex Group for Securities Violations

MRX

Legal Proceedings

Accounting Changes

Financial Restatement

Faruqi & Faruqi, LLP is investigating Marex Group plc (NASDAQ: MRX) for potential federal securities law violations.
The investigation focuses on investors who purchased or acquired securities between May 16, 2024, and August 5, 2025.
A federal securities class action has been filed, and the deadline for investors to seek the role of lead plaintiff is December 8, 2025.
Allegations include Marex selling over-the-counter financial instruments to itself, inconsistencies in its financial statements, and that its financial statements could not be relied upon.
Following a NINGI Research report on August 5, 2025, accusing Marex of a multi-year accounting scheme, Marex's stock dropped 6.2%, closing at $35.31.

Nov 8, 2025, 6:22 AM

Press Release

MRX Reports Strong Q3 2025 Financial Results and Strategic Acquisitions

MRX

Earnings

Revenue Acceleration/Inflection

M&A

MRX reported a 25% year-on-year increase in Q3 2025 Adjusted Profit Before Tax to $101 million, with year-to-date Adjusted Profit Before Tax reaching $303 million, up 26% year-on-year.
Revenue for Q3 2025 grew 24% year-on-year to $485 million, contributing to a year-to-date revenue of $1.45 billion, a 23% increase year-on-year.
The company's Adjusted Basic EPS for Q3 2025 was $1.01, marking a 23% increase year-on-year, and its Adjusted Return on Equity stood at 27.6%.
MRX continued its growth strategy by announcing the acquisitions of Winterflood Securities and Valcourt, enhancing its UK cash equities business and fixed income capabilities, respectively.
Management expressed optimism for the full year 2025 and beyond, noting a strong start to the fourth quarter and positioning for approximately 10% organic profit growth.

Nov 6, 2025, 2:00 PM

Presentation

Marex Reports Strong Q3 2025 Performance Driven by Diversification and M&A

MRX

Earnings

M&A

Revenue Acceleration/Inflection

Marex (MRX) reported a strong Q3 2025, with adjusted profit before tax of $101 million, up 25% year-on-year, and revenues of $485 million, up 24% year-on-year. For the first nine months of 2025, adjusted profit before tax reached $303 million and revenues were $1.45 billion.
The company achieved an adjusted basic EPS of $1.01 per share for Q3 2025, a 23% increase year-on-year, and maintained a strong adjusted return on equity of 27.6%.
Strategic diversification has reduced the proportion of profit strongly linked to exchange volumes from approximately 70% in 2023 to 54% today, with Prime Services now contributing nearly a quarter of total profits and generating $57 million in Q3 2025 revenue.
Marex is actively expanding through M&A, including the announced acquisition of Winterflood, and saw strong performance from recent acquisitions like Hamilton Court, which contributed $20 million in Q3 revenue.
Management expressed optimism for the remainder of 2025, with Q4 starting very strongly and October being a record month, anticipating a record fourth quarter and sustainable profit growth in the 10%-20% range.

Nov 6, 2025, 2:00 PM

Transcript

Marex Group plc Announces Strong Third Quarter 2025 Results

MRX

Earnings

M&A

Dividends

Marex Group plc reported strong Q3 2025 financial results, with revenue increasing 24% year-on-year to $484.6 million and Adjusted Profit Before Tax growing 25% to $100.5 million.
For the nine months ended September 30, 2025, revenue rose 23% to $1,452.0 million and Adjusted Profit Before Tax increased 26% to $303.2 million.
The company's performance was significantly driven by growth in its Prime services business and strong Clearing operations, which saw a 4% growth in average client balances to $13.3 billion.
Strategic execution included the acquisitions of Winterflood Securities on July 25 and Valcourt on October 22, and the reaffirmation of an Investment Grade credit rating by S&P on September 23.
A Q3 2025 dividend of $0.15 per share was approved, to be paid in the fourth quarter of 2025.

Nov 6, 2025, 12:25 PM

6-K

Marex Group Faces Securities Class Action Investigation

MRX

Legal Proceedings

Accounting Changes

Financial Restatement

Faruqi & Faruqi, LLP is investigating Marex Group plc (MRX) following a federal securities class action alleging false and misleading statements and undisclosed financial inconsistencies.
The complaint details accusations of Marex selling over-the-counter financial instruments to itself and having unreliable financial statements due to intercompany issues.
A NINGI Research report on August 5, 2025, accused Marex of a multi-year accounting scheme, including a $17 million fabricated receivable and concealed $1 billion in derivatives exposure.
Following the report, Marex's stock dropped 6.2%, closing at $35.31.
The deadline for investors who suffered losses exceeding $50,000 between May 16, 2024, and August 5, 2025, to seek lead plaintiff status is December 8, 2025.

Nov 3, 2025, 2:53 PM

Press Release

Marex Group Faces Securities Class Action Investigation

MRX

Legal Proceedings

Financial Restatement

Accounting Changes

Faruqi & Faruqi, LLP is investigating Marex Group plc (NASDAQ: MRX) for alleged federal securities law violations, with a December 8, 2025 deadline for investors to seek lead plaintiff status in a class action lawsuit.
The complaint alleges Marex made false and/or misleading statements, including selling over-the-counter financial instruments to itself and having inconsistencies in its financial statements, rendering them unreliable.
On August 5, 2025, NINGI Research released a report accusing Marex of a multi-year accounting scheme involving off-balance-sheet entities, fictitious transactions, and misleading disclosures to hide losses and inflate profits, including concealing nearly $1 billion in derivatives exposure.
Following the report, Marex's stock dropped 6.2%, closing at $35.31.
The investigation covers securities purchased or acquired between May 16, 2024 and August 5, 2025.

Oct 28, 2025, 1:47 PM

Press Release

Marex Group Faces Securities Class Action Investigation

MRX

Legal Proceedings

Financial Restatement

Accounting Changes

Faruqi & Faruqi, LLP is investigating Marex Group plc (NASDAQ: MRX) and a federal securities class action has been filed, with a December 8, 2025, deadline for investors to seek lead plaintiff status.
The class action covers investors who purchased Marex securities between May 16, 2024, and August 5, 2025.
The complaint alleges Marex made false or misleading statements and failed to disclose issues such as selling over-the-counter financial instruments to itself and inconsistencies in financial statements, leading to unreliable financial reporting.
A NINGI Research report on August 5, 2025, accused Marex of a multi-year accounting scheme, citing a $17 million fabricated receivable and concealed nearly $1 billion in derivatives exposure.
Following the report, Marex's stock dropped 6.2%, closing at $35.31 on August 5, 2025.

Oct 15, 2025, 2:44 PM

Press Release

Marex Group plc Announces Share Purchases by Directors and Officers

MRX

On October 10, 2025, CEO Ian Lowitt acquired 32,465 ordinary shares, increasing his total holding to 2,615,016 ordinary shares.
On October 13, 2025, Paolo Tonucci, Chief Strategist and CEO of Capital Markets, purchased 30,000 ordinary shares, bringing his total holding to 1,108,342 ordinary shares.
On October 14, 2025, former Marex Board members Sir Jeremy Isaacs and Roger Nagioff each acquired 35,000 ordinary shares.
These purchases follow earlier acquisitions in August by Non-Executive Chairman Robert Pickering (2,700 ordinary shares) and Board member Konstantin Graf von Schweinitz (7,100 ordinary shares).
CEO Ian Lowitt stated that these acquisitions underscore the executive leadership team's strong belief in Marex's growth trajectory and future potential, with the team collectively owning more than 7% of the company.

Oct 15, 2025, 1:38 PM

6-K

Marex announces CEO share purchase

MRX

Marex Group plc announced that its Chief Executive Officer, Ian Lowitt, purchased 32,465 ordinary shares in the open market on October 10.
Following this purchase, Ian Lowitt's total holding in Marex Group plc is 2,615,016 ordinary shares.
This announcement was made via a press release on October 13, 2025, and subsequently filed as a Form 6-K on October 14, 2025.